GB9523752D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number: GB9523752D0
Authority: GB; United Kingdom
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 1995-11-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

GBGB9523752.5A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PFIZER Ltd

Pfizer Ltd Great Britain

Original Assignee

PFIZER Ltd

Pfizer Ltd Great Britain

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1995-11-21

Publication date

1996-01-24

1995-11-21 Priority to GBGB9523752.5A priority Critical patent/GB9523752D0/en

1995-11-21 Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd

1996-01-24 Publication of GB9523752D0 publication Critical patent/GB9523752D0/en

1996-11-11 Priority to HU9903734A priority patent/HUP9903734A3/en

1996-11-11 Priority to AU75721/96A priority patent/AU709560B2/en

1996-11-11 Priority to CA002232715A priority patent/CA2232715A1/en

1996-11-11 Priority to EP96938215A priority patent/EP0862437A1/en

1996-11-11 Priority to PL96326981A priority patent/PL326981A1/en

1996-11-11 Priority to SK630-98A priority patent/SK63098A3/en

1996-11-11 Priority to KR1019980703777A priority patent/KR19990071505A/en

1996-11-11 Priority to JP9519364A priority patent/JPH10513481A/en

1996-11-11 Priority to PCT/EP1996/005020 priority patent/WO1997018814A1/en

1996-11-11 Priority to TR1998/00902T priority patent/TR199800902T2/en

1996-11-11 Priority to CN96198486A priority patent/CN1215993A/en

1996-11-11 Priority to CZ981554A priority patent/CZ155498A3/en

1996-11-11 Priority to NZ322053A priority patent/NZ322053A/en

1996-11-11 Priority to BR9611626A priority patent/BR9611626A/en

1996-11-20 Priority to TNTNSN96141A priority patent/TNSN96141A1/en

1996-11-20 Priority to ZA9609722A priority patent/ZA969722B/en

1996-11-20 Priority to MA24397A priority patent/MA26410A1/en

1996-11-20 Priority to ARP960105252A priority patent/AR004335A1/en

1996-11-20 Priority to PE1996000831A priority patent/PE22898A1/en

1996-11-20 Priority to YU62096A priority patent/YU62096A/en

1996-11-21 Priority to HR9523752.5A priority patent/HRP960554A2/en

1996-11-21 Priority to APAP/P/1996/000883A priority patent/AP718A/en

1996-11-21 Priority to CO96061449A priority patent/CO4480020A1/en

1998-03-31 Priority to IS4706A priority patent/IS4706A/en

1998-05-08 Priority to BG102438A priority patent/BG102438A/en

1998-05-19 Priority to OA9800058A priority patent/OA10687A/en

1998-05-20 Priority to MX9804008A priority patent/MX9804008A/en

1998-05-20 Priority to NO982302A priority patent/NO982302L/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

GBGB9523752.5A 1995-11-21 1995-11-21 Pharmaceutical formulations Pending GB9523752D0 (en)

Priority Applications (29)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
BR9611626A BR9611626A (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
SK630-98A SK63098A3 (en)	1995-11-21	1996-11-11	Controlled-release pharmaceutical formulation, process for its preparation and use of polyethyleneoxide
JP9519364A JPH10513481A (en)	1995-11-21	1996-11-11	Pharmaceutical preparations
CA002232715A CA2232715A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
EP96938215A EP0862437A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
PL96326981A PL326981A1 (en)	1995-11-21	1996-11-11	Pharmaceutic preparations
HU9903734A HUP9903734A3 (en)	1995-11-21	1996-11-11	Controlled-release pharmaceutical formulations for oral administration and method for preparing this
KR1019980703777A KR19990071505A (en)	1995-11-21	1996-11-11	Pharmaceutical preparations
AU75721/96A AU709560B2 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
TR1998/00902T TR199800902T2 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations.
CN96198486A CN1215993A (en)	1995-11-21	1996-11-11	Pharmaceutical formulations
CZ981554A CZ155498A3 (en)	1995-11-21	1996-11-11	A controlled release pharmaceutical composition, a method for producing the same, and the use of polyethylene oxide
NZ322053A NZ322053A (en)	1995-11-21	1996-11-11	Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
TNTNSN96141A TNSN96141A1 (en)	1995-11-21	1996-11-20	PHARMACEUTICAL FORMULATIONS AND PROCESS FOR THEIR PRODUCTION
YU62096A YU62096A (en)	1995-11-21	1996-11-20	Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof
ZA9609722A ZA969722B (en)	1995-11-21	1996-11-20	Pharmaceutical formulations.
MA24397A MA26410A1 (en)	1995-11-21	1996-11-20	PHARMACEUTICAL FORMULATIONS AND PROCESS FOR THEIR PRODUCTION.
ARP960105252A AR004335A1 (en)	1995-11-21	1996-11-20	PHARMACEUTICAL FORMULATIONS
PE1996000831A PE22898A1 (en)	1995-11-21	1996-11-20	PHARMACEUTICAL FORMULATIONS
CO96061449A CO4480020A1 (en)	1995-11-21	1996-11-21	PHARMACEUTICAL FORMULATIONS
APAP/P/1996/000883A AP718A (en)	1995-11-21	1996-11-21	A controlled-release pharmaceutical formulation for oral administration.
HR9523752.5A HRP960554A2 (en)	1995-11-21	1996-11-21	Pharmaceutical formulations
IS4706A IS4706A (en)	1995-11-21	1998-03-31	pharmaceutical compositions
BG102438A BG102438A (en)	1995-11-21	1998-05-08	Medicamentous form
OA9800058A OA10687A (en)	1995-11-21	1998-05-19	Pharmaceutical formulations
MX9804008A MX9804008A (en)	1995-11-21	1998-05-20	Pharmaceutical formulations.
NO982302A NO982302L (en)	1995-11-21	1998-05-20	Pharmaceutical composition

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
GB9523752D0 true GB9523752D0 (en)	1996-01-24

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB9523752.5A Pending GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (en)
JP (1)	JPH10513481A (en)
KR (1)	KR19990071505A (en)
CN (1)	CN1215993A (en)
AP (1)	AP718A (en)
AR (1)	AR004335A1 (en)
AU (1)	AU709560B2 (en)
BG (1)	BG102438A (en)
BR (1)	BR9611626A (en)
CA (1)	CA2232715A1 (en)
CO (1)	CO4480020A1 (en)
CZ (1)	CZ155498A3 (en)
GB (1)	GB9523752D0 (en)
HR (1)	HRP960554A2 (en)
HU (1)	HUP9903734A3 (en)
IS (1)	IS4706A (en)
MA (1)	MA26410A1 (en)
MX (1)	MX9804008A (en)
NO (1)	NO982302L (en)
NZ (1)	NZ322053A (en)
OA (1)	OA10687A (en)
PE (1)	PE22898A1 (en)
PL (1)	PL326981A1 (en)
SK (1)	SK63098A3 (en)
TN (1)	TNSN96141A1 (en)
TR (1)	TR199800902T2 (en)
WO (1)	WO1997018814A1 (en)
YU (1)	YU62096A (en)
ZA (1)	ZA969722B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
ES2258300T3 (en) *	1997-12-16	2006-08-16	Pfizer Products Inc.	COMBINATION OF ANTAGONISTS OF THE ALFA-1-ADRENERGIC RECEIVER AND A GMPC PDEV INHIBITOR FOR THE TREATMENT OF IMPOTENCE.
EA003101B1 (en)	1998-03-19	2002-12-26	Бристол-Майерз Сквибб Компани	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) *	1998-05-15	2000-10-14	Pfizer	PHARMACEUTICAL FORMULATIONS.
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
CO5140079A1 (en) *	1998-10-14	2002-03-22	Novartis Ag	PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) *	2003-10-17	2005-04-28	Ranbaxy Laboratories Limited	Oral matrix formulations of doxazosin
US20050255157A1 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) *	2004-05-28	2006-04-27	한미약품 주식회사	Sustained release composition for oral administration of niacin
DE102004054054A1 (en)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) *	2004-11-20	2007-02-07	대우약품공업주식회사	Sustained-release tablets containing doxazosin
AU2006284053B2 (en) *	2005-08-22	2010-04-22	Novartis Ag	Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
US7722898B2 (en)	2006-04-26	2010-05-25	Supernus Pharmaceuticals, Inc.	Modified-release preparations containing oxcarbazepine and derivatives thereof
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
KR101452915B1 (en)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	Polymorphism
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN100396282C (en) *	2006-07-25	2008-06-25	山东省医药工业研究所	Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en)	2008-03-11	2009-09-17	Depomed Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (en)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	FORMULATIONS INVOLVING A DPP4 INHIBITOR
KR20190016601A (en)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	Treatment for diabetes in patients inappropriate for metformin therapy
TWI478712B (en)	2008-09-30	2015-04-01	Astellas Pharma Inc	Pharmaceutical composition for modified release
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en)	2008-12-17	2010-12-24	동아제약주식회사	Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
PT2395983T (en)	2009-02-13	2020-07-03	Boehringer Ingelheim Int	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AR076341A1 (en)	2009-04-20	2011-06-01	Elcelyx Therapeutics Inc	THERAPIES BASED ON BINDINGS OF CHEMIOSENSORIAL RECEPTORS. TREATMENT METHOD COMPOSITION
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
KR20120107080A (en)	2009-11-27	2012-09-28	베링거 인겔하임 인터내셔날 게엠베하	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
KR101927068B1 (en)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
MY161846A (en)	2010-07-09	2017-05-15	James Trinca Green	Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
SG189444A1 (en)	2010-10-19	2013-05-31	Elcelyx Therapeutics Inc	Chemosensory receptor ligand-based therapies
AR083878A1 (en)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
SI2661266T1 (en)	2011-01-07	2021-01-29	Anji Pharma (Us) Llc	Chemosensory receptor ligand-based therapies
CN102058555A (en) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	Doxazosin controlled release tablet
UY33937A (en)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN102188431A (en) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	Doxazosin mesylate sustained-release tablets and preparation method thereof
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en)	2011-05-17	2014-02-25	Mallinckrodt Llc	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (en)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014197744A1 (en)	2013-06-05	2014-12-11	Synchroneuron, Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6615109B2 (en)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Medical use of DPP-4 inhibitors
CN105616378A (en) *	2014-10-31	2016-06-01	康普药业股份有限公司	Fluconazole capsule and preparation method therefor
MX390363B (en)	2016-06-10	2025-03-20	Boehringer Ingelheim Int	Combinations of linagliptin and metformin
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (en) *	1982-07-06	1988-12-21	Lepetit Spa	A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
MX9100277A (en) *	1990-07-23	1992-02-28	Alza Corp	ORAL OSMOTIC DEVICE FOR APPLYING NICOTINE

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Ceased
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Ceased
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2232715A1 (en)	1997-05-29
NO982302D0 (en)	1998-05-20
BR9611626A (en)	1999-06-01
ZA969722B (en)	1998-05-20
MX9804008A (en)	1998-09-30
IS4706A (en)	1998-03-31
PL326981A1 (en)	1998-11-09
NZ322053A (en)	1999-11-29
JPH10513481A (en)	1998-12-22
AU709560B2 (en)	1999-09-02
HUP9903734A2 (en)	2000-03-28
CN1215993A (en)	1999-05-05
KR19990071505A (en)	1999-09-27
MA26410A1 (en)	2004-12-20
WO1997018814A1 (en)	1997-05-29
NO982302L (en)	1998-07-17
CO4480020A1 (en)	1997-07-09
AP718A (en)	1999-01-06
SK63098A3 (en)	1999-05-07
BG102438A (en)	1999-01-29
HUP9903734A3 (en)	2000-04-28
AU7572196A (en)	1997-06-11
CZ155498A3 (en)	1999-03-17
PE22898A1 (en)	1998-05-07
OA10687A (en)	2002-11-27
TR199800902T2 (en)	1998-09-21
YU62096A (en)	1999-03-04
AP9600883A0 (en)	1997-01-31
EP0862437A1 (en)	1998-09-09
TNSN96141A1 (en)	2005-03-15
HRP960554A2 (en)	1998-02-28
AR004335A1 (en)	1998-11-04

Publication	Publication Date	Title
EG23826A (en)	2007-09-25	Pharmaceutical formulations
AP9600883A0 (en)	1997-01-31	Pharmaceutical formulations
GB9408117D0 (en)	1994-06-15	Pharmaceutical formulations
GB9519363D0 (en)	1995-11-22	Pharmaceutical formulation
GB9404248D0 (en)	1994-04-20	Pharmaceutical formulations
EP0862431A4 (en)	1999-07-07	Pharmaceutical formulation
ZA967827B (en)	1997-03-18	Pharmaceutical compositions
EG24294A (en)	2009-01-08	Pharmaceutical compositions
GB9506382D0 (en)	1995-05-17	Pharmaceutical compositions
GB9513972D0 (en)	1995-09-06	Pharmaceutical compositions
GB9523566D0 (en)	1996-01-17	Pharmaceutical formulation
ZA96526B (en)	1996-08-06	Novel pharmaceutical formulation
AP9801196A0 (en)	1998-03-31	Pharmaceutical preparation
ZA96392B (en)	1996-08-29	Pharmaceutical formulations
GB9413542D0 (en)	1994-08-24	Pharmaceutical formulations
GB9500978D0 (en)	1995-03-08	Pharmaceutical formulations
ZA967542B (en)	1997-03-20	Pharmaceutical combination preparation comprising keto-profen
GB9516584D0 (en)	1995-10-11	Pharmaceutical formulations
GB9508989D0 (en)	1995-06-21	Pharmaceutical formulations
GB9503752D0 (en)	1995-04-12	Pharmaceutical formulations
HUP9602732A2 (en)	1997-09-29	Pharmaceutical composition comprising lanperisone
GB9408161D0 (en)	1994-06-15	Pharmaceutical formulations
GB9414216D0 (en)	1994-08-31	Pharmaceutical formulations
GB9401738D0 (en)	1994-03-23	Pharmaceutical formulations
GB9408163D0 (en)	1994-06-15	Pharmaceutical formulations